01—Abstract
Summary
Summary of the 10-Q filed November 6, 2024. Cited figures are marked; the original filing is the authoritative source.
Charles River Laboratories International, Inc.'s Form 10-Q for the quarter ended September 28, 2024 shows total revenue of $1,009.8 milliona for the three months, down $16.9 million or 1.6% from $1,026.6 million a year earlier, and $3,047.4 million for the nine months, down $68.5 million or 2.2%.
The decline was driven mainly by lower volume in the DSA segment, partly offset by growth in Manufacturing and the Noveprim acquisition. Operating income fell to $117.4 millionb (11.6% of revenue) for the quarter from $151.5 million, and to $395.0 million (13.0% of revenue) for the nine months from $484.3 million. The filing attributes the drop mainly to lower revenue and restructuring charges of $30.6 million in the quarter and $65.6 million year to date.
Net income attributable to common shareholders was $68.7 millionc for the quarter (diluted EPS $1.33) and $226.0 million for the nine months (diluted EPS $4.37). Cash flow from operations improved to $575.2 million for the nine months, up from $463.0 million, while capital expenditures fell to $157.4 million from $240.2 million. Long-term debt, net and finance leases declined to $2.33 billion from $2.65 billion, mainly from net repayments on the revolving facility.
The company repurchased 0.5 million shares for $100.7 milliond under a new $1.0 billion authorization approved August 2, 2024, leaving $899.3 million available. The filing also reports that the company is cooperating with U.S. DOJ, USFWS and SEC investigations into its non-human primate supply chain, and that a putative securities class action was dismissed in July 2024 and is on appeal.
The company says it cannot estimate the potential exposure from these matters. In the DSA segment, the Discovery Services goodwill reporting unit's fair value exceeded its carrying value by approximately 22%, and no impairment was recognized.
02—Key points
Key Highlights
- Total revenue of $1,009.8 million for Q3 2024, down $16.9 million or 1.6% from $1,026.6 million; nine-month revenue of $3,047.4 million, down 2.2%.
- Operating income of $117.4 million (11.6% of revenue) in the quarter versus $151.5 million (14.8%) a year earlier, reflecting lower DSA volume and restructuring charges of $30.6 million.
- Diluted EPS of $1.33 for the quarter versus $1.69, and $4.37 for the nine months versus $5.58.
- Operating cash flow rose to $575.2 million for the nine months from $463.0 million, while capital expenditures fell to $157.4 million from $240.2 million.
- Long-term debt, net and finance leases fell to $2.33 billion from $2.65 billion at year-end 2023, mainly from net repayments on the revolving facility.
- A new $1.0 billion stock repurchase authorization was approved on August 2, 2024; $899.3 million remains, and 0.5 million shares were repurchased for $100.7 million.
- The company expects approximately $200 million in annualized cost savings from restructuring actions, of which approximately $100 million will affect fiscal 2024.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q3 FY2024, Charles River Laboratories International kept $0.07.
- Revenue$1.01B100.0%
- Cost of revenue−$660.7M65.4%
- Gross profit$349.0M34.6%
- Operating costs−$231.6M22.9%
- Operating income$117.4M11.6%
- Interest, other & tax−$48.7M4.8%
- Net income$68.7M6.8%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2024filed November 6, 2024Financial Statements
Q3 FY2024 against Q3 FY2023
| Line item | Q3 FY2024Q3 FY2023 | Change |
|---|---|---|
| Revenue | $1.01B$1.03B | −1.6% |
| Cost of Revenue | $660.74M$664.78M | −0.6% |
| Gross Profit | $349.02M$361.84M | −3.5% |
| SG&A Expenses | $199.21M$176.11M | +13.1% |
| Operating Income | $117.41M$151.50M | −22.5% |
| Net Income | $68.68M$87.39M | −21.4% |
| EPS (Basic) | $1.34$1.70 | −21.2% |
| EPS (Diluted) | $1.33$1.69 | −21.3% |
| Shares Outstanding (Basic) | 51.39M51.28M | +0.2% |
| Shares Outstanding (Diluted) | 51.58M51.61M | 0.0% |
05—Questions
Frequently Asked Questions
Why did revenue and operating income decline this quarter?
The filing says revenue fell mainly because DSA volume declined, with DSA revenue down $49.0 million, or 7.4%, for the quarter. Operating income also absorbed restructuring charges of $30.6 million, higher unallocated corporate costs of $76.8 million, and higher amortization and an inventory step-up tied to the Noveprim acquisition. Manufacturing and RMS revenue rose, partially offsetting the decline.
What is the status of the non-human primate investigations and litigation?
The company is cooperating with DOJ, USFWS and SEC investigations and has voluntarily suspended shipments of non-human primates from Cambodia to the United States. The securities class action was dismissed on July 1, 2024, and the plaintiff has appealed. Two derivative lawsuits are stayed pending the outcome of the class action. The company says it cannot predict the outcome or estimate the potential exposure.
How much goodwill is at risk in the Discovery Services business?
A triggering event led to a quantitative goodwill test for the Discovery Services reporting unit. Its fair value exceeded carrying value by approximately 22%, so no impairment was recognized as of September 28, 2024. The filing notes that the unit's fair value could fall and cause an impairment if cash flows fall short of estimates or market multiples decline. The goodwill carrying value for the unit is $334.8 million.
How is the company using its cash?
For the nine months, operating cash flow of $575.2 million covered capital expenditures of $157.4 million and net repayments of $346.2 million on the Credit Facility. The company also spent $100.7 million on share repurchases under the program and $18.4 million on share netting for tax withholding, and paid $12.0 million to acquire the remaining equity interest in another redeemable noncontrolling interest.
06—Continue